Clinical trial · Interventional
Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)
IMRT With Concurrent Chemotherapy and Cetuximab Against Locoregionally Advanced NPC: a Phase 1 Study
NCT01712919CI-TRIAL-00014090completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators will add weekly cetuximab (c225) to the standard care of chemoradiation against locoregionally advanced Nasopharyngeal Carcinoma (NPC), and evaluate the toxicity and efficacy of this new regimen.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cetuximab | Biological | Cetuximab | ALIAS |
| Concurrent chemotherapy with paclitaxel and nedaplatin | Drug | — | UNRESOLVED |
| Intensity-modulated radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- cetuximab
- description
- Patients will be given intensity-modulated radiotherapy,2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin,and weekly cetuximab during radiation therapy.
- interventionNames
- Radiation: Intensity-modulated radiotherapy
- Drug: Concurrent chemotherapy with paclitaxel and nedaplatin
- Biological: Cetuximab
Primary outcomes (2)
- measure
- Number of Participants with Adverse Events as a Measure of Safety
- timeFrame
- 6 months
- measure
- Number of Participants with Adverse Events as a Measure of Safety and tolerability
- timeFrame
- 6 months
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed untreated NPC patients * locoregionally advanced (T3-4 or N2-3 M0) * 18-65 years * with MRI examinations * ECOG ≤ 2 * With written consent Exclusion Criteria: * Without a second cancer * Pregnancy * With other severe diseases (blood,liver ,kidney or heart diseases) * Could not be staged properly * Without written consent
References
Publications (0)
Data not yet available
No reference posted for this study.